- GLP-1 receptor agonists copy a natural gut hormone that boosts insulin after meals, lowers glucagon, slows digestion and increases fullness.
- They lower A1C and weight substantially, and several have been shown to lower the risk of heart attack, stroke and kidney decline.
- Stomach side effects are common at first. Starting low, increasing slowly and eating smaller meals helps most people.
Few medicines have attracted as much attention in recent years as the GLP-1 family. They are prescribed for type 2 diabetes and, at different doses and under different brand names, for weight management. This article explains how they work and what to expect if your doctor suggests one. Examples include semaglutide (weekly injection or daily tablet), dulaglutide and liraglutide. Tirzepatide acts on GLP-1 and a second hormone, GIP, and is often grouped with them.
What GLP-1 does in your body
GLP-1 (glucagon-like peptide-1) is an “incretin” hormone released by your gut when you eat. It tells the body that food has arrived. In type 2 diabetes, this signal is weaker. The medicines mimic GLP-1 but last much longer, from a day to a whole week.
The pancreas releases more insulin when glucose is high, so on their own these medicines rarely cause lows.
Lower glucagon means the liver releases less sugar after meals.
Food enters the gut more gradually, which blunts after-meal spikes.
Signals to the brain reduce appetite and “food noise”, which supports weight loss.
What the evidence shows
Because of these results, the American Diabetes Association recommends a GLP-1 medicine with proven benefit for people with type 2 diabetes who have heart disease or are at high risk, and now also for those with chronic kidney disease, regardless of their A1C. They are also a first-line option for people who need to lose weight.
Starting treatment: go low and slow
To let your digestive system adjust, GLP-1 medicines start at a low dose and increase step by step, usually every four weeks. The first dose is not meant to lower blood sugar much.
Mild nausea, fullness or reduced appetite are common. Eat smaller meals.
Side effects may return briefly after each increase, then settle.
A1C and weight begin to fall more noticeably. Your prescriber decides whether to increase further.
Benefits continue while you take it. Stopping usually leads to weight regain and higher glucose.
Managing side effects
Nausea, burping, bloating, diarrhea or constipation affect many people, mostly in the first weeks and after dose increases. These tips help:
- Eat slowly, and stop at the first sign of fullness.
- Choose smaller meals; limit greasy, fried and very sweet foods.
- Drink water through the day; sip rather than gulp.
- Avoid lying down straight after eating.
- Include protein at each meal and keep up strength exercise to protect muscle as you lose weight.
- Ask about a slower dose increase if symptoms are bothersome.
Contact your doctor promptly if you have: severe, persistent stomach pain (possibly spreading to the back), repeated vomiting or signs of dehydration, pain in the upper right abdomen or yellowing of the skin, or a lump or swelling in the neck.
Also tell your prescriber if: you have had pancreatitis; you or a family member have had medullary thyroid cancer or MEN2 syndrome; you have diabetic eye disease (rapid A1C drops can briefly worsen it); you are pregnant, planning pregnancy or breastfeeding; or you are having surgery or a procedure under sedation, because slower stomach emptying matters for anesthesia.
If you also take insulin or a sulfonylurea, your dose may need lowering to avoid low blood sugar.
MythGLP-1 medicines do all the work, so diet and exercise do not matter.
FactThey work best alongside healthy eating and activity. Protein and strength training help ensure weight lost is mostly fat, not muscle.
Practical questions
- How do I inject? Most come as pre-filled pens with very fine needles, injected under the skin of the abdomen, thigh or upper arm. Your nurse or pharmacist will show you.
- What if I miss a dose? Rules differ by product. Check the leaflet or ask your pharmacist.
- Are compounded or online versions safe? Regulators have warned about dosing errors and unapproved products. Use medicines from a licensed pharmacy with a prescription.
Common questions
How much weight do people lose on GLP-1 medicines?
It varies widely. In people with type 2 diabetes, average weight loss in trials is often in the range of about 4–10% of body weight, and more with the higher doses used for weight management or with tirzepatide. Some people lose much more, others very little.
Can I drink alcohol while taking a GLP-1 medicine?
Moderate alcohol is not forbidden, but many people find they want less. Alcohol can worsen nausea and adds empty calories. If you also take insulin or a sulfonylurea, alcohol raises the risk of delayed low blood sugar.
What happens if I stop taking it?
Appetite usually returns and most people regain much of the weight they lost within a year, with blood sugar rising again. If cost or side effects are a problem, talk to your prescriber about options rather than stopping suddenly.
- GLP-1 medicines work on the pancreas, liver, stomach and brain.
- They lower A1C and weight, and several protect the heart and kidneys.
- Start low, go slow, and eat smaller, protein-rich meals.
- Next: Taking your medicines consistently.
Type 2 Diabetes Basics: all 18 articles
- What Is Type 2 Diabetes?
- Type 2 Diabetes Risk Factors
- Early Signs and Symptoms
- How Type 2 Diabetes Is Diagnosed
- A1C vs Blood Glucose
- Diabetes and Your Heart
- Preventing Long-Term Complications
- Type 2 Diabetes Medicines Explained
- GLP-1 Medicines: What to Expect
- Taking Your Medicines Consistently
- When Your Diabetes Changes
- Digital Tools: Meters, CGMs and Apps
- How to Read a Nutrition Label
- Carb Counting Made Simple
- Small Food Swaps for Lower Blood Sugar
- Travelling With Diabetes
- Diabetes Distress and Depression
- Caring for Someone With Type 2 Diabetes
Sources
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756.
- Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375:311–322.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221–2232.
- Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391:109–121.
- American Diabetes Association Professional Practice Committee. Summary of Revisions: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S6.
- US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss.
This article is for general education and is not a substitute for advice from your own doctor, diabetes educator or pharmacist.